# TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

> **NCT02705755** · PHASE2 · COMPLETED · sponsor: **Theravance Biopharma** · enrollment: 34 (actual)

## Conditions studied

- Neurogenic Orthostatic Hypotension
- Multiple System Atrophy (MSA) With Orthostatic Hypotension
- Pure Autonomic Failure
- Parkinson Disease
- Hypotension, Orthostatic
- Orthostatic Hypotension
- Pure Autonomic Failure With Orthostatic Hypotension
- Parkinson Disease With Orthostatic Hypotension

## Interventions

- **DRUG:** TD-9855
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02705755
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-09
- **Primary completion:** 2018-07-24
- **Final completion:** 2018-11-28
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02705755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02705755, "TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02705755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*